Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory Myopathies.

Patrick M. Grogan1, Jonathan S. Katz

  • 1Department of Neurology, Wilford Hall Medical Center, 2200 Bergquist Drive, Suite 1,San Antonio, TX 78236, USA.

Current Treatment Options in Neurology
|February 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myasthenia Gravis.

Current treatment options in neurology·2004
Same author

Chronic Inflammatory Demyelinating Polyneuropathy.

Current treatment options in neurology·2003
Same author

Asymmetric Acquired Demyelinating Polyneuropathies: MMN and MADSAM.

Current treatment options in neurology·2001
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Idiopathic inflammatory myopathies are treated with immunosuppressants. Corticosteroids are the main treatment, while intravenous immunoglobulin (IVIg) is effective for dermatomyositis but not polymyositis. Inclusion body myositis shows poor response to therapies.

Area of Science:

  • Rheumatology and Immunology
  • Neurology
  • Pharmacology

Background:

  • Idiopathic inflammatory myopathies (IIMs) are chronic autoimmune diseases characterized by muscle inflammation.
  • Current treatments primarily involve immunosuppressive therapies targeting the immune system.
  • Dermatomyositis (DM) and polymyositis (PM) are the subtypes most responsive to immunotherapy.

Purpose of the Study:

  • To review current therapeutic strategies for idiopathic inflammatory myopathies.
  • To evaluate the efficacy and limitations of various immunosuppressive treatments, including corticosteroids, intravenous immunoglobulin (IVIg), and other agents.
  • To highlight the distinct treatment responses observed in different IIM subtypes, particularly DM, PM, and inclusion body myositis (IBM).

Main Methods:

Related Experiment Videos

  • Review of existing clinical trials and expert clinical practice regarding IIM treatments.
  • Analysis of the effectiveness, side effect profiles, and cost-effectiveness of different therapeutic options.
  • Comparison of treatment responses across DM, PM, and IBM, noting discrepancies in current classifications.

    • Main Results:

    • High-dose oral prednisone remains the cornerstone treatment for DM and PM, despite lack of randomized controlled trials.
    • Intravenous immunoglobulin (IVIg) is effective for DM, often used as a second-line or adjunctive therapy due to cost and administration challenges.
    • Chronic immunosuppressants (azathioprine, cyclosporine, methotrexate) are options for refractory cases, requiring close monitoring; newer agents are under investigation. IBM shows poor response to immunosuppression.

    Conclusions:

    • Treatment strategies for IIMs are primarily based on immunosuppression, with corticosteroids as the mainstay.
    • IVIg offers a viable option for DM, but its use is limited by practical considerations.
    • The distinct clinical and therapeutic profiles of DM, PM, and IBM suggest that grouping them solely by inflammation may obscure important differences in pathogenesis and treatment response.